79 related articles for article (PubMed ID: 28095160)
1. Minimal Loss of Lifetime for Patients With Diffuse Large B-Cell Lymphoma in Remission and Event Free 24 Months After Treatment: A Danish Population-Based Study.
Jakobsen LH; Bøgsted M; Brown PN; Arboe B; Jørgensen J; Larsen TS; Juul MB; Schurmann L; Højberg L; Bergmann OJ; Lassen T; Josefsson PL; Jensen P; Johnsen HE; El-Galaly TC
J Clin Oncol; 2017 Mar; 35(7):778-784. PubMed ID: 28095160
[TBL] [Abstract][Full Text] [Related]
2. Single-agent MOR208 salvage and maintenance therapy in a patient with refractory/relapsing diffuse large B-cell lymphoma: a case report.
Jurczak W; Bryk AH; Mensah P; Gałązka K; Trofimiuk-Müldner M; Wyrobek Ł; Sawiec A; Skotnicki AB
J Med Case Rep; 2016 May; 10(1):123. PubMed ID: 27178351
[TBL] [Abstract][Full Text] [Related]
3. Frequency of Complete Remission With R-CHOP Therapy in Patients With Diffuse Large B Cell Lymphoma.
Hassan SU; Hussain S; Fakhar M; Ahmad A; Durrani F
Cureus; 2024 Apr; 16(4):e57368. PubMed ID: 38694660
[TBL] [Abstract][Full Text] [Related]
4. Survival after diffuse large B-cell lymphoma among children, adolescents, and young adults in California, 2001-2014: A population-based study.
Abrahão R; Ribeiro RC; Lichtensztajn DY; Rosenberg AS; Keegan THM
Pediatr Blood Cancer; 2019 Apr; 66(4):e27559. PubMed ID: 30511461
[TBL] [Abstract][Full Text] [Related]
5. Treatment cost and life expectancy of diffuse large B-cell lymphoma (DLBCL): a discrete event simulation model on a UK population-based observational cohort.
Wang HI; Smith A; Aas E; Roman E; Crouch S; Burton C; Patmore R
Eur J Health Econ; 2017 Mar; 18(2):255-267. PubMed ID: 26969332
[TBL] [Abstract][Full Text] [Related]
6. Cause-specific mortality in a population-level cohort of diffuse large B-cell lymphoma following chemotherapy in the early 21st century.
Bei LY; Shang CY; Wu JZ; Shen HR; Yin H; Liang JH; Zhang XY; Wang L; Li JY; Li Y; Xu W
Ann Hematol; 2024 May; 103(5):1675-1685. PubMed ID: 38228775
[TBL] [Abstract][Full Text] [Related]
7. Socioeconomic disparities in mortality after diffuse large B-cell lymphoma in the modern treatment era.
Tao L; Foran JM; Clarke CA; Gomez SL; Keegan TH
Blood; 2014 Jun; 123(23):3553-62. PubMed ID: 24705494
[TBL] [Abstract][Full Text] [Related]
8. Impaired Immune Health in Survivors of Diffuse Large B-Cell Lymphoma.
Shree T; Li Q; Glaser SL; Brunson A; Maecker HT; Haile RW; Levy R; Keegan THM
J Clin Oncol; 2020 May; 38(15):1664-1675. PubMed ID: 32083991
[TBL] [Abstract][Full Text] [Related]
9. Danish National Lymphoma Registry.
Arboe B; Josefsson P; Jørgensen J; Haaber J; Jensen P; Poulsen C; Rønnov-Jessen D; Pedersen RS; Pedersen P; Frederiksen M; Pedersen M; de Nully Brown P
Clin Epidemiol; 2016; 8():577-581. PubMed ID: 27822102
[TBL] [Abstract][Full Text] [Related]
10. Simplicity at the cost of predictive accuracy in diffuse large B-cell lymphoma: a critical assessment of the R-IPI, IPI, and NCCN-IPI.
Biccler J; Eloranta S; de Nully Brown P; Frederiksen H; Jerkeman M; Smedby KE; Bøgsted M; El-Galaly TC
Cancer Med; 2018 Jan; 7(1):114-122. PubMed ID: 29239133
[TBL] [Abstract][Full Text] [Related]
11. 2021 Update on Diffuse large B cell lymphoma: A review of current data and potential applications on risk stratification and management.
Susanibar-Adaniya S; Barta SK
Am J Hematol; 2021 May; 96(5):617-629. PubMed ID: 33661537
[TBL] [Abstract][Full Text] [Related]
12. Challenges and Opportunities in the Management of Diffuse Large B-Cell Lymphoma in Older Patients.
Di M; Huntington SF; Olszewski AJ
Oncologist; 2021 Feb; 26(2):120-132. PubMed ID: 33230948
[TBL] [Abstract][Full Text] [Related]
13. Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient-Level Analysis of Multiple Randomized Trials (SEAL).
Shi Q; Schmitz N; Ou FS; Dixon JG; Cunningham D; Pfreundschuh M; Seymour JF; Jaeger U; Habermann TM; Haioun C; Tilly H; Ghesquieres H; Merli F; Ziepert M; Herbrecht R; Flament J; Fu T; Coiffier B; Flowers CR
J Clin Oncol; 2018 Sep; 36(25):2593-2602. PubMed ID: 29975624
[TBL] [Abstract][Full Text] [Related]
14. Treatment strategies and outcomes in diffuse large B-cell lymphoma among 1011 patients aged 75 years or older: A Danish population-based cohort study.
Juul MB; Jensen PH; Engberg H; Wehberg S; Dessau-Arp A; Haziri D; Kristensen HB; Baech J; Schurmann L; Clausen MR; Valentin R; Knudsen LM; Munksgaard L; El-Galaly TC; Frederiksen H; Larsen TS
Eur J Cancer; 2018 Aug; 99():86-96. PubMed ID: 29935491
[TBL] [Abstract][Full Text] [Related]
15. Long-term survival and loss in expectancy of life in a population-based cohort of 7114 patients with diffuse large B-cell lymphoma.
Ekberg S; Jerkeman M; Andersson PO; Enblad G; Wahlin BE; Hasselblom S; Andersson TM; Eloranta S; Smedby KE
Am J Hematol; 2018 May; ():. PubMed ID: 29770496
[TBL] [Abstract][Full Text] [Related]
16. Prediction of 5-year overall survival of diffuse large B-cell lymphoma on the pola-R-CHP regimen based on 2-year event-free survival and progression-free survival.
Zhang WR; Liu X; Zhong QZ; Wu T; Yang Y; Chen B; Jing H; Tang Y; Jin J; Liu YP; Song YW; Fang H; Lu NN; Li N; Zhai YR; Zhang WW; Wang SL; Chen F; Yin L; Qi SN; Li YX
Cancer Med; 2024 Jan; 13(1):. PubMed ID: 38180169
[TBL] [Abstract][Full Text] [Related]
17. Genetic and transcriptomic analyses of diffuse large B-cell lymphoma patients with poor outcomes within two years of diagnosis.
Ren W; Wan H; Own SA; Berglund M; Wang X; Yang M; Li X; Liu D; Ye X; Sonnevi K; Enblad G; Amini RM; Sander B; Wu K; Zhang H; Wahlin BE; Smedby KE; Pan-Hammarström Q
Leukemia; 2024 Mar; 38(3):610-620. PubMed ID: 38158444
[TBL] [Abstract][Full Text] [Related]
18. Challenges for quality and utilization of real-world data for diffuse large B-cell lymphoma in REALYSA, a LYSA cohort.
Ghesquières H; Cherblanc F; Belot A; Micon S; Bouabdallah KK; Esnault C; Fornecker LM; Thokagevistk K; Bonjour M; Bijou F; Haioun C; Morineau N; Ysebaert L; Damaj G; Tessoulin B; Guidez S; Morschhauser F; Thiéblemont C; Chauchet A; Gressin R; Jardin F; Fruchart C; Labouré G; Fouillet L; Lionne-Huyghe P; Bonnet A; Lebras L; Amorim S; Leyronnas C; Olivier G; Guieze R; Houot R; Launay V; Drénou B; Fitoussi O; Detourmignies L; Abraham J; Soussain C; Lachenal F; Pica GM; Fogarty P; Cony-Makhoul P; Bernier A; Le Guyader-Peyrou S; Monnereau A; Boissard F; Rossi C; Camus V
Blood Adv; 2024 Jan; 8(2):296-308. PubMed ID: 37874913
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological analysis of diffuse large B-cell lymphoma using molecular biomarkers: a retrospective analysis from 7 Hungarian centers.
Balikó A; Szakács Z; Kajtár B; Ritter Z; Gyenesei A; Farkas N; Kereskai L; Vályi-Nagy I; Alizadeh H; Pajor L
Front Oncol; 2023; 13():1224733. PubMed ID: 37746254
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of post-treatment serum soluble interleukin-2 receptor in newly diagnosed diffuse large B-cell lymphoma patients who achieved complete metabolic response following R-CHOP therapy.
Shirouchi Y; Nishimura N; Mishima Y; Ishihara Y; Asai H; Tamba M; Hirano M; Hirano K; Teramoto Y; Yoshida K; Takeuchi K; Terauchi T; Maruyama D
Sci Rep; 2023 Aug; 13(1):13713. PubMed ID: 37608029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
